ABSTRACT
Medical intensive care medicine treats patients with severe, potentially life-threatening diseases covering the complete spectrum of internal medicine. The qualification in medical intensive care medicine requires a broad spectrum of knowledge and skills in medical intensive care medicine, but also in the general field of internal medicine. Both sides of the coin must be taken into account, the treatment with life-sustaining strategies of the acute illness of the patient and also the treatment of patient's underlying chronic diseases. The indispensable foundation of medical intensive care medicine as described in this curriculum includes basic knowledge and skills (level of competence I-III) as well as of behavior and attitudes. This curriculum is primarily dedicated to the internist in advanced training in medical intensive care medicine. However, this curriculum also intends to reach trainers in intensive care medicine and also the German physician chambers with their examiners, showing them which knowledge, skills as well as behavior and attitudes should be taught to trainees according to the education criteria of the German Society of Medical Intensive Care and Emergency Medicine (DGIIN).
Subject(s)
Emergency Medicine , Critical Care , Curriculum , Emergency Medicine/education , Humans , Internal MedicineABSTRACT
BACKGROUND: Tracheostomy in ventilated patients suffering from Coronavirus disease 2019 (COVID-19) carries an increased risk of exposure to virus-containing aerosol for the staff. OBJECTIVE: Evaluation of a risk-reduced procedure for tracheostomy. METHOD: Presentation of "hybrid tracheostomy": a method combining the advantages of conventional surgical and percutaneous dilative tracheostomy. RESULTS: Tracheostomy of six patients using the hybrid method without any complications. CONCLUSION: "Hybrid tracheostomy" offers a minimally invasive and safe procedure with low risk of exposure to virus-containing aerosol.
Subject(s)
Coronavirus Infections , Coronavirus , Pandemics , Pneumonia, Viral , Tracheostomy , Betacoronavirus , COVID-19 , Humans , SARS-CoV-2ABSTRACT
There is a widespread use of biomarkers in modern intensive care. The potential benefit for the patients is, however, not fully investigated. This paper will discuss biomarkers regarding the diagnosis of infections and their potential use in antibiotic stewardship programs (ABS) in order to guide antimicrobial therapy. In the field of infections, procalcitonin (PCT) seems to be the most widespread marker. PCT is able to differentiate between inflammation and infection. Also, in the context of ABS rounds, PCT is well established.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Sepsis , Biomarkers , Calcitonin/blood , Calcitonin Gene-Related Peptide , Humans , Protein Precursors , Sepsis/diagnosis , Sepsis/drug therapyABSTRACT
BACKGROUND: Intensive care patients with renal failure or insufficiency comprise a heterogeneous group of subjects with widely differing metabolic patterns and nutritional requirements. They include subjects with various stages of acute kidney injury (AKI), acute-on-chronic renal failure (A-CKD), without/with renal replacement therapy (RRT), chronic kidney disease (CKD), and subjects on regular hemodialysis or peritoneal dialysis therapy (HD/PD). GOALS: Development of recommendations by the renal section of DGIIN (Deutsche Gesellschaft für Internistische Intensivmedizin und Notfallmedizin), ÖGIAIN (Österreichische Gesellschaft für Internistische und Allgemeine Intensivmedizin und Notfallmedizin) and DIVI (Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin) for the metabolic management and the planning, indication, implementation, and monitoring of nutrition therapy in this heterogeneous group of patients. MATERIALS AND METHODS: The recommendations are based on recent evidence and current recommendations of DGEM (Deutsche Gesellschaft für Ernährungsmedizin), ASPEN (American Society for Parenteral and Enteral Nutrition) and ESPEN (European Society for Clinical Nutrition and Metabolism) and also the KDGIO (Kidney Disease: Improving Global Outcomes) clinical practice guidelines for AKI and the expert knowledge and clinical experience of the authors. RESULTS: Nutrition support in these patient groups is not fundamentally different from that in other disease states but must consider the multiple variations in metabolism and nutrient requirements. Nutrition therapy must be adapted to the stage of disease and especially, in those patients on RRT. Nutritional needs can differ widely between patients but also in the same patient during the course of the disease. CONCLUSIONS: Thus, the patient with renal failure requires an individualized approach in nutrition support and because of the altered metabolism of many nutrients and intolerances for electrolytes and fluids, the nutrition support in patients with renal insufficiency requires close clinical and laboratory monitoring.
Subject(s)
Acute Kidney Injury , Critical Illness , Nutritional Support , Renal Replacement Therapy , Acute Kidney Injury/therapy , Critical Care , Enteral Nutrition , Humans , KidneyABSTRACT
BACKGROUND: Regional citrate anticoagulation (RCA) in continuous renal replacement therapy can effectively anticoagulate dialysis circuits without having adverse effects on systemic heparin application. In particular, in continuous renal replacement therapy RCA is well established and represents a safe procedure with longer filter lifetimes and fewer bleeding complications. OBJECTIVES: To provide guidance on the indications, advantages and disadvantages, and use of RCA, current recommendations from the renal section of the DGIIN (Deutschen Gesellschaft für Internistische Intensivmedizin und Notfallmedizin), ÖGIAIN (Österreichischen Gesellschaft für Internistische und Allgemeine Intensivmedizin und Notfallmedizin) and DIVI (Deutschen Interdisziplinären Vereinigung für Intensiv- und Notfallmedizin) are stated. MATERIALS AND METHODS: The recommendations in this paper are based on the current KDIGO (Kidney Disease: Improving Global Outcomes) guidelines, other published guidelines and protocols as well as the expert knowledge and clinical experience of the authors. RESULTS: The use of commercially available machines with coupled pumps and integrated safety features, effective personal training and standardized protocols for clinical usage (SOP) is particularly important for the safe clinical use of RCA in renal replacement therapy. Contrary to previous recommendations, even liver failure or shock with lactic acidosis may no longer be an absolute contra-indication for RCA. However, these particular patients have to be carefully monitored for signs of citrate accumulation.
Subject(s)
Acute Kidney Injury , Anticoagulants , Citric Acid , Renal Replacement Therapy , Acute Kidney Injury/therapy , Anticoagulants/therapeutic use , Citrates , Citric Acid/therapeutic use , Critical Care , HumansABSTRACT
BACKGROUND: Acute kidney injury (AKI) is a common complication in intensive care unit (ICU) patients. The incidence of AKI in ICU patients exceeds 50% and the associated morbidity and mortality rates increase with severity of AKI. In addition, long-term consequences of AKI are underestimated and several studies show impaired long-term outcome after AKI. In about 5-25% of ICU patients with AKI renal replacement therapy (RRT) is required. OBJECTIVES: To assist in indication, timing, modality and application of renal replacement therapy of adult patients, current recommendations from the renal sections of the DGIIN (Deutschen Gesellschaft für Internistische Intensivmedizin und Notfallmedizin), ÖGIAIN (Österreichischen Gesellschaft für Internistische und Allgemeine Intensivmedizin und Notfallmedizin) and DIVI (Deutschen Interdisziplinären Vereinigung für Intensiv- und Notfallmedizin) are stated. MATERIALS AND METHODS: The recommendations stated in this paper are based on the current KDIGO (Kidney Disease: Improving Global Outcomes) guidelines, recommendations from the 17th Acute Disease Quality Initiative (ADQI) Consensus Group, the French Intensive Care Society (SRLF) with the French Society of Anesthesia Intensive Care (SFAR) and the expert knowledge and clinical experience of the authors. RESULTS: Today, different treatment modalities for RRT are available. Although continuous RRT and intermittent dialysis therapy as well as continuous dialysis therapy have comparable outcomes, differences exist with respect to practical application as well as health-economic aspects. Individualized risk stratification might be helpful to choose the right time to start and the right treatment modality for patients.
Subject(s)
Acute Kidney Injury , Critical Care , Renal Replacement Therapy , Acute Kidney Injury/therapy , Adult , Humans , Intensive Care Units , Kidney/physiopathology , Renal DialysisABSTRACT
BACKGROUND: Many anti-infective drugs require dose adjustments in critically ill patients with acute kidney injury (AKI) and renal replacement therapy, in order to achieve adequate therapeutic drug concentrations. OBJECTIVES: The fundamental pharmacokinetic and pharmacodynamic principles of drug dose adjustment are presented. Recommendations on anti-infective drug dosage in intensive care are provided. MATERIALS AND METHODS: We established dose recommendations of selected anti-infective drugs based on information in the summary of product characteristics, published studies and recommendations, pharmacokinetic and pharmacodynamic considerations, and the experience and expert opinion of the authors. RESULTS: Out of a total of 37 anti-infective drugs (31 antibiotics, 2 antivirals, 4 antifungals) 8 can be administered independent of renal function. For 29 anti-infective drugs, a specific recommendation on drug dosage could be made in case of intermittent hemodialysis and for 24 anti-infective drugs in case of continuous hemo(dia)filtration. CONCLUSIONS: Recommendations on dosing of important anti-infective drugs in critically ill patients with AKI and renal replacement therapy are provided.
Subject(s)
Acute Kidney Injury , Renal Replacement Therapy , Acute Kidney Injury/therapy , Critical Care , Critical Illness , HumansABSTRACT
BACKGROUND: Acute kidney injury (AKI) has both high mortality and morbidity. OBJECTIVES: To prevent the occurrence of AKI, current recommendations from the renal section of the DGIIN (Deutschen Gesellschaft für Internistische Intensivmedizin und Notfallmedizin), ÖGIAIN (Österreichischen Gesellschaft für Internistische und Allgemeine Intensivmedizin und Notfallmedizin) and DIVI (Deutschen Interdisziplinären Vereinigung für Intensiv- und Notfallmedizin) are stated. MATERIALS AND METHODS: The recommendations stated in this paper are based on the current Kidney Disease Improving Global Outcomes (KDIGO) guidelines, the published statements of the "Working Group on Prevention, AKI section of the European Society of Intensive Care Medicine" and the expert knowledge and clinical experience of the authors. RESULTS: Currently there are no approved clinically effective drugs for the prevention of AKI. Therefore the mainstay of prevention is the optimization of renal perfusion by improving the mean arterial pressure (>65â¯mmâ¯Hg, higher target may be considered in hypertensive patients). This can be done by vasopressors, preferably norepinephrine and achieving or maintaining euvolemia. Hyperhydration that can lead to AKI itself should be avoided. In patients with maintained diuresis this can be done by diuretics that are per se no preventive drug for AKI. Radiocontrast enhanced imaging should not be withheld from patients at risk for AKI; if indicated, however, the contrast media should be limited to the smallest possible volume.
Subject(s)
Acute Kidney Injury , Critical Care , Acute Kidney Injury/therapy , Critical Illness , HumansSubject(s)
Organ Dysfunction Scores , Sepsis , Early Diagnosis , Emergency Service, Hospital , HumansABSTRACT
Sepsis is still the leading cause of mortality in noncardiac intensive care units. The new definition of sepsis emphasizes the importance of organ dysfunction. The Sepsis-related Organ Failure Assessment (SOFA) score is an indicator for organ dysfunction. The diagnosis of sepsis is for the most part made on clinical parameters with an altered mental status being a very sensitive indicator. Microbiological work-up is essential and two sets of blood cultures are the recommended minimum. Management includes prompt initiation of adequate antibiotic treatment and swift fluid resuscitation. Overinfusion is to be avoided as this itself can have a negative impact on patient outcome.
Subject(s)
Intensive Care Units , Sepsis/diagnosis , Sepsis/therapy , Anti-Bacterial Agents/therapeutic use , Bacteriological Techniques , Early Diagnosis , Early Medical Intervention , Humans , Multiple Organ Failure/diagnosis , Multiple Organ Failure/therapy , Prognosis , Shock, Septic/diagnosis , Shock, Septic/therapyABSTRACT
BACKGROUND: Acute kidney injury (AKI) is an important organ failure, which has an enormous negative impact on outcome in patients with severe sepsis. METHODS: In this paper, the pathophysiological causes as well as noninterventional and interventional (extracorporeal) treatment of patients with AKI and severe sepsis are described. RESULTS: The cornerstone of noninterventional therapy is infection control and heamodynamic stabilization with fluid resuscitation and vasopressors. In patients with deteriorating AKI, extracorporeal treatment should be started early. Generally, continuous and intermittent modes are considered to be equally effective and possible. In practice, a continuous form is preferred in hemodynamically unstable patients. DISCUSSION: The idea that AKI may easily be overcome by starting extracorporeal treatment is no longer true. AKI is much more complex. The dynamic process of the disease should be kept in mind when choosing the correct mode and dose of the extracorporeal treatment. Antibiotic dosage must be adjusted when kidney function is improving or deteriorating.
Subject(s)
Acute Kidney Injury/physiopathology , Sepsis/physiopathology , Acute Kidney Injury/mortality , Acute Kidney Injury/therapy , Catecholamines/administration & dosage , Fluid Therapy , Hemodynamics/physiology , Humans , Intensive Care Units , Kidney Function Tests , Renal Dialysis/methods , Sepsis/mortality , Sepsis/therapy , Survival RateSubject(s)
Sepsis/diagnosis , Sepsis/therapy , Shock, Septic/diagnosis , Shock, Septic/therapy , HumansABSTRACT
Practice guidelines are systematically developed statements and recommendations that assist the physicians and patients in making decisions about appropriate health care measures for specific clinical circumstances taking into account specific national health care structures. The 1(st) revision of the S-2k guideline of the German Sepsis Society in collaboration with 17 German medical scientific societies and one self-help group provides state-of-the-art information (results of controlled clinical trials and expert knowledge) on the effective and appropriate medical care (prevention, diagnosis, therapy and follow-up care) of critically ill patients with severe sepsis or septic shock. The guideline had been developed according to the "German Instrument for Methodological Guideline Appraisal" of the Association of the Scientific Medical Societies (AWMF). In view of the inevitable advancements in scientific knowledge and technical expertise, revisions, updates and amendments must be periodically initiated. The guideline recommendations may not be applied under all circumstances. It rests with the clinician to decide whether a certain recommendation should be adopted or not, taking into consideration the unique set of clinical facts presented in connection with each individual patient as well as the available resources.
Subject(s)
Continuity of Patient Care/standards , Critical Care/standards , Emergency Medical Services/standards , Patient Care Team/standards , Sepsis , Follow-Up Studies , Germany , Humans , Sepsis/diagnosis , Sepsis/prevention & control , Sepsis/therapySubject(s)
Sepsis/prevention & control , Sepsis/therapy , Anti-Bacterial Agents/therapeutic use , Anti-Infective Agents, Local , Decontamination , Fluid Therapy , Hemodynamics/physiology , Humans , Infection Control , Infections/blood , Infections/diagnosis , Meningitis, Bacterial/diagnosis , Meningitis, Bacterial/prevention & control , Meningitis, Bacterial/therapy , Pneumonia, Ventilator-Associated/diagnosis , Pneumonia, Ventilator-Associated/prevention & control , Pneumonia, Ventilator-Associated/therapy , Sepsis/diagnosis , Sepsis/rehabilitation , Surgical Wound Infection/diagnosis , Surgical Wound Infection/prevention & control , Surgical Wound Infection/therapy , Terminology as TopicABSTRACT
In the commentary by Zander et al. the authors appear concerned about the methods and results of our, at that time, unpublished sepsis trial evaluating hydroxyethyl starch (HES) and insulin therapy. Unfortunately, the authors' concerns are based on false assumptions about the design, conduct and modes of action of the compounds under investigation. For instance, in our study the HES solution was not used for maintenance of daily fluid requirements, so that the assumption of the authors that this colloid was used "exclusively" is wrong. Moreover, the manufacturer of Hemohes, the HES product we used, gives no cut-off value for creatinine, thus the assumption that this cut-off value was "doubled" in our study is also incorrect. Other claims by the authors such as that lactated solutions cause elevated lactate levels, iatrogenic hyperglycemia and increase O(2) consumption are unfounded. There is no randomized controlled trial supporting such a claim - this claim is neither consistent with our study data nor with any credible published sepsis guidelines or with routine practice worldwide. We fully support open scientific debate. Our study methods and results have now been published after a strict peer-reviewing process and this data is now open to critical and constructive reviewing. However, in our opinion this premature action based on wrong assumptions and containing comments by representatives of pharmaceutical companies does not contribute to a serious, unbiased scientific discourse.
